코엔원

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapy and medication isn't effective. A customized treatment could be the solution.

Cue is a digital intervention platform that converts passively collected smartphone sensor data into personalized micro-interventions designed to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to discover their feature predictors and uncover distinct characteristics that can be used to predict changes in mood over time.

Predictors of Mood

Depression is the leading cause of mental illness across the world.1 Yet only half of those with the condition receive treatment. To improve the outcomes, doctors must be able identify and treat patients who are most likely to respond to certain treatments.

The ability to tailor depression treatments is one method of doing this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit most from certain treatments. They use sensors on mobile phones and a voice assistant incorporating artificial intelligence as well as other digital tools. With two grants totaling over $10 million, they will employ these techniques to determine the biological and behavioral factors that determine responses medicine to treat anxiety and depression antidepressant medications as well as psychotherapy.

So far, the majority of research on factors that predict depression treatment effectiveness has focused on the sociodemographic and clinical aspects. These include demographics like gender, age and education, as well as clinical aspects like severity of symptom, comorbidities and biological markers.

A few studies have utilized longitudinal data to predict mood in individuals. Few also take into account the fact that moods vary significantly between individuals. Therefore, it is essential to create methods that allow the determination of different mood predictors for each person and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can systematically identify various patterns of behavior and emotion that differ between individuals.

In addition to these methods, the team created a machine learning algorithm to model the dynamic variables that influence each person's mood. The algorithm blends the individual differences to produce a unique "digital genotype" for each participant.

This digital phenotype has been linked to CAT DI scores, a psychometrically validated symptom severity scale. The correlation was low however (Pearson r = 0,08, BH adjusted P-value 3.55 x 10 03) and varied widely between individuals.

Predictors of Symptoms

post pregnancy depression treatment Stroke Depression Treatment (Lovewiki.Faith) is among the most prevalent causes of disability1, but it is often underdiagnosed and undertreated2. In addition the absence of effective alternative treatments for depression and stigma associated with depressive disorders prevent many people from seeking help.

To facilitate personalized treatment in order to provide a more personalized treatment, identifying predictors of symptoms is important. Current prediction methods rely heavily on clinical interviews, which are not reliable and only reveal a few features associated with depression.

Using machine learning to blend continuous digital behavioral phenotypes that are captured by sensors on smartphones and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory, the CAT-DI) together with other predictors of symptom severity could improve the accuracy of diagnosis and homeopathic treatment for depression efficacy for depression. These digital phenotypes are able to capture a variety of unique actions and behaviors that are difficult to record through interviews, and allow for continuous and high-resolution measurements.

The study involved University of California Los Angeles students with mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical care in accordance with their severity of depression. Participants with a CAT-DI score of 35 or 65 were allocated online support via a peer coach, while those with a score of 75 patients were referred to clinics in-person for psychotherapy.

At baseline, participants provided a series of questions about their personal demographics and psychosocial characteristics. The questions asked included education, age, sex and gender, marital status, financial status and whether they were divorced or not, their current suicidal thoughts, intent or attempts, and how often they drank. The CAT-DI was used to rate the severity of depression symptoms on a scale from 100 to. The CAT-DI test was performed every two weeks for participants who received online support and weekly for those who received in-person care.

Predictors of the Reaction to Treatment

Personalized depression treatment is currently a research priority and many studies aim at identifying predictors that will help clinicians determine the most effective medication for each patient. Particularly, pharmacogenetics is able to identify genetic variations that affect how the body metabolizes antidepressants. This allows doctors select medications that are most likely to work for every patient, minimizing time and effort spent on trial-and-error treatments and avoid any negative side negative effects.

Another promising approach is building prediction models using multiple data sources, including data from clinical studies and neural imaging data. These models can be used to determine the variables that are most predictive of a particular outcome, such as whether a medication can improve mood or symptoms. These models can be used to determine the response of a patient to a treatment, which will help doctors maximize the effectiveness.

A new type of research employs machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to combine the effects of many variables and improve the accuracy of predictive. These models have been shown to be useful in predicting the outcome of treatment like the response to antidepressants. These approaches are gaining popularity in psychiatry, and it is likely that they will become the norm for future clinical practice.

In addition to prediction models based on ML, research into the underlying mechanisms of depression is continuing. Recent findings suggest that the disorder is associated with dysfunctions in specific neural circuits. This suggests that an individualized treatment for depression will depend on targeted therapies that restore normal functioning to these circuits.

One way to do this is to use internet-based interventions that can provide a more individualized and tailored experience for patients. For example, one study found that a web-based program was more effective than standard treatment in improving symptoms and providing the best quality of life for patients suffering from MDD. A controlled, randomized study of a personalized treatment for depression found that a significant number of participants experienced sustained improvement as well as fewer side consequences.

Predictors of adverse effects

In the treatment of depression, a major challenge is predicting and identifying which antidepressant medication will have very little or no adverse negative effects. Many patients are prescribed a variety drugs before they find a drug that is both effective and well-tolerated. Pharmacogenetics provides a novel and exciting way to select antidepressant drugs that are more effective and specific.

Many predictors can be used to determine which antidepressant to prescribe, including gene variants, patient phenotypes (e.g. gender, sex or ethnicity) and co-morbidities. However it is difficult to determine the most reliable and accurate factors that can predict the effectiveness of a particular treatment is likely to require controlled, randomized trials with much larger samples than those that are typically part of clinical trials. This is because it may be more difficult to detect the effects of moderators or interactions in trials that comprise only one episode per participant rather than multiple episodes over a period of time.

Additionally, the estimation of a patient's response to a specific medication will also likely require information about the symptom profile and comorbidities, as well as the patient's prior subjective experiences with the effectiveness and tolerability of the medication. There are currently only a few easily assessable sociodemographic variables and clinical variables appear to be consistently associated with response to MDD. These include age, gender and race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to depression treatment is still in its infancy and there are many hurdles to overcome. First it is necessary to have a clear understanding of the genetic mechanisms is essential and an understanding of what is a reliable predictor of treatment response. Ethics such as privacy and the ethical use of genetic information must also be considered. Pharmacogenetics could be able to, over the long term help reduce stigma around mental health treatment and improve treatment outcomes. Like any other psychiatric treatment, it is important to take your time and carefully implement the plan. At present, the most effective course of action is to offer patients a variety of effective medications for depression and encourage them to talk freely with their doctors about their concerns and experiences.